Key result
Oral ranolazine added to amiodarone speeds POAF conversion by ~5 hours post-CABG in HFrEF.
Why the study?
Does adding oral ranolazine to standard intravenous amiodarone shorten the time to conversion of postoperative atrial fibrillation to sinus rhythm in patients with HFrEF undergoing elective on-pump CABG surgery?
RCT (n=511)
Single-blind
prospective, randomized, allocation-concealed
No
Does adding oral ranolazine to standard intravenous amiodarone shorten the time to conversion of postoperative atrial fibrillation to sinus rhythm in patients with HFrEF undergoing elective on-pump CABG surgery?
Answers are grounded in this paper and cite their sources.
Adding a single oral dose of ranolazine to standard intravenous amiodarone safely and significantly accelerates conversion of postoperative atrial fibrillation to sinus rhythm in HFrEF patients after CABG surgery.
Postoperative atrial fibrillation (POAF) in patients with systolic heart failure constitutes an emerging situation, particularly when occurring after cardiac surgery. Amiodarone (A) alone is generally insufficient in achieving a fast termination of AF independently from left ventricular systolic function and atrial size. Recent investigations showed faster restoration of sinus rhythm (SR) by the combination of A and ranolazine (R) in patients with preserved systolic function. In this prospective, randomized, allocation-concealed, single-blind, single-site clinical trial, we enrolled 511 consecutive eligible patients with reduced ejection fraction (<40%) heart failure (HF-REF) who developed POAF after elective on-pump CABG surgery. A 35% of these patients reported at least one episode of paroxysmal AF within the last 6 months. Preoperatively, none patient had episodes of AF. All participants were randomized to receive either 500 mg oral R given once at the time of randomization plus intravenous standard dosing regimen of A (256 patients, 65±9 years, 86% male) or A alone at the same dosage (255 patients, 66±10 years, 88% male). Preoperative left ventricular EF values were well balanced in both groups (36.5±4.7% in the A+R treated patients vs 36.4±4.6% in the A-only treated patients). Left atrial diameter did not significantly differ between the two groups (4.7±0.2 vs 4.8±0.3 cm in the A+R vs A group, respectively). Mean time to conversion of POAF was significantly shorter in the A+R vs A group (9.1±0.8 vs 14.4±3.9 hours, respectively; P<.0001). Arrhythmia conversion rate during 24 hours post intervention was 91.8% in the A+R treated patients and 14.5% in the A group (p<.0001). Post conversion heart rate was significantly lower in the drug-combination group vs the A-only group (77±8 vs 93±10 bpm, P<0.0001). QTc intervals were shorter in the A+R group vs A-only group (409±19 vs 428±24 ms, P<0.0001). No considerable cardiac or noncardiac clinically evident adverse effects were noted especially in patients receiving R as add-on therapy. In conclusion, A+R treatment for conversion of POAF after cardiac surgery in patients with HF-REF was safe and more efficacious than A monotherapy, as indicated by significantly faster SR restoration.
No takes yet. Share an insight, caveat, or question.
Simopoulos et al. (2017) conducted an RCT in Postoperative atrial fibrillation (POAF) in patients with reduced ejection fraction heart failure (HF-REF) undergoing elective on-pump CABG surgery (n=511). Ranolazine plus Amiodarone vs. Intravenous standard dosing regimen of amiodarone alone was evaluated on Mean time to conversion of postoperative atrial fibrillation (hours) (p=<.0001). Adding oral ranolazine to IV amiodarone shortened time to POAF conversion and increased 24-h conversion rates in HFrEF post-CABG.
Synapse has enriched 10 related papers. Consider them for comparative context: